Nov. 14 at 2:44 PM
$BLGO 1/2
- Everyone’s waiting for one thing - sales.
- The groundwork is already laid with multiple distribution agreements:
- International and EMEA distribution partners.
- Advanced Solutions LLC (U.S. nationwide agreement).
- A major “Gorilla Partner” preparing for launch - name under wraps until the reveal, and for good reason.
- The key question: can these partners convert and sell ClyraSept products that outperform every competitor - products many experts see as transformational for wound care, and possibly for healthcare overall?
- The CEO, who knows the internal numbers, has publicly stated multiple times that Clyra’s valuation could exceed
$500 million within two years.
- Yet today, BioLargo’s total market cap sits around
$50 million - despite holding a 49% stake in Clyra.
- A reevaluation seems inevitable once actual sales begin and results become visible.
TBC